Syncom Formulation (India) (NSE:SYNCOMF) EPS (Basic): ₹0.89 (TTM As of Mar. 2026)


NSE:SYNCOMF Syncom Formulation (India) Ltd NSE:SYNCOMF
93 GF Score
Price ₹13.89
GF Value ₹19.78
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Syncom Formulation (India) EPS (Basic)?

Syncom Formulation (India) NSE:SYNCOMF -0.36% 93 EPS (Basic) is ₹0.89 as of Mar. 2026. GuruFocus rates NSE:SYNCOMF with a GF Score™ of 93/100 and a GF Value™ of ₹19.78 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Syncom Formulation (India)'s basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was ₹0.27. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.89.

Syncom Formulation (India)'s EPS (Diluted) for the three months ended in Mar. 2026 was ₹0.27. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.89.

Syncom Formulation (India)'s EPS without NRI for the three months ended in Mar. 2026 was ₹0.27. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 0.89.

During the past 12 months, Syncom Formulation (India)'s average EPS without NRIGrowth Rate was 52.80% per year. During the past 3 years, the average EPS without NRI Growth Rate was 55.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 20.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was 17.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Syncom Formulation (India)'s highest 3-Year average EPS without NRI Growth Rate was 209.90% per year. The lowest was -71.00% per year. And the median was 7.90% per year.

Syncom Formulation (India)  (NSE:SYNCOMF) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Syncom Formulation (India) EPS (Basic) Related Terms

Syncom Formulation (India) EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Syncom Formulation (India)'s EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syncom Formulation (India) EPS (Basic) Chart

Syncom Formulation (India) Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.26 0.22 0.27 0.53 0.81

Syncom Formulation (India) Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.21 0.18 0.23 0.27
NSE:SYNCOMF
93GF Score
Syncom Formulation (India) Ltd NSE:SYNCOMF
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syncom Formulation (India) EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Syncom Formulation (India)'s Basic EPS for the fiscal year that ended in Mar. 2026 is calculated as

Basic EPS (A: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(764.38-0)/943.679
=0.81

Syncom Formulation (India)'s Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(251.744-0)/932.385
=0.27

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of ₹0.89 mean?
Syncom Formulation (India) (NSE:SYNCOMF) has a EPS (Basic) of ₹0.89 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Syncom Formulation (India) and its competitors.
Is Syncom Formulation (India)'s EPS (Basic) too high?
Syncom Formulation (India)'s current EPS (Basic) is ₹0.89. Overall, Syncom Formulation (India) has a GF Score™ of 93/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syncom Formulation (India)'s EPS (Basic) compare to ZTS?
Syncom Formulation (India)'s EPS (Basic) of ₹0.89 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Syncom Formulation (India) and its competitors. Syncom Formulation (India)'s current EPS (Basic) is ₹0.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syncom Formulation (India) stock overvalued right now?
Based on GuruFocus' analysis, Syncom Formulation (India) (NSE:SYNCOMF) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹19.78, compared to a current price of ₹13.89 — trading 29.8% below its estimated fair value. The current EPS (Basic) is ₹0.89. Syncom Formulation (India)'s overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Syncom Formulation (India) (NSE:SYNCOMF), the current EPS (Basic) is ₹0.89 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Syncom Formulation (India) (NSE:SYNCOMF) Overvalued in 2026?

Based on GuruFocus' analysis, Syncom Formulation (India) stock appears to be undervalued. The current stock price of ₹13.89 is trading 29.8% below its estimated GF Value™ of ₹19.78. GuruFocus considers Syncom Formulation (India) to be Significantly Undervalued.

Key valuation signals for NSE:SYNCOMF:

  • EPS (Basic): ₹0.89
  • GF Value™: ₹19.78 vs. price of ₹13.89 (29.8% below fair value)
  • GF Score™: 93/100 with 2 warning signs

No single metric tells the full story. See the NSE:SYNCOMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Syncom Formulation (India) Business Description

Other Exchanges 524470:India
Address 207, Saket Nagar, Near Saket Club, Indore, MP, IND, 452018
Syncom Formulation (India) Ltd is in the business of pharmaceuticals. The company operates through three segments including manufacturing and dealings in Pharmaceutical drugs and formulations, Trading of commodities, and Renting of property. It manufactures and markets pharmaceutical formulation products in various dosage forms like tablets, capsules, liquids orals, liquids vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and Herbals. The company's product includes generic, antiviral, antidepressant, cough suppressant, electrolyte, histamine, estrogen, and much more. It generates maximum revenue through the Pharmaceutical drugs and formulations segment.
93GF Score

Get the complete analysis for NSE:SYNCOMF

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹13.89
Price
₹19.78
GF Value